The global market for oral psoriasis treatment amounts to KRW 5 trillion. In the Korean market, generic medicines are likely to dominate. The original medicine company withdrew its drug from the Korean market due to dissatisfaction with the reimbursement decision, whereas generic medicines are likely to accept the term.

A new type of oral medicine is likely to be competitive because psoriasis treatments that are available in South Korea are primarily injectables.

The Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review held its 10th meeting for 2024 on October 10th and ruled that medicines containing apremilast would be appropriate for reimbursement coverage if